Edition:
United States

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

154.70CHF
27 Jul 2016
Change (% chg)

CHF-3.40 (-2.15%)
Prev Close
CHF158.10
Open
CHF157.00
Day's High
CHF158.00
Day's Low
CHF152.20
Volume
16,357
Avg. Vol
10,703
52-wk High
CHF175.00
52-wk Low
CHF137.30

COPN.S

Chart for COPN.S

About

COSMO Pharmaceuticals SA is a Luxembourg-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin... (more)
No analyst recommendations are available for COPN.S.

Overall

Beta: --
Market Cap(Mil.): €2,091.99
Shares Outstanding(Mil.): 14.42
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 36.73 37.52
EPS (TTM): 0.24 -- --
ROI: 5.61 15.28 14.48
ROE: 6.12 16.33 15.65

BRIEF-Cosmo: successful outcome of phase III clinical trial for Rifamycin SV MMX

* Cosmo announces successful outcome of phase III clinical trial for Rifamycin SV MMX Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 06 2016

BRIEF-COSMO Pharmaceuticals FY net profit up at EUR 248.2 mln

* FY net profit 248.2 million euros ($278.06 million) versus 73.3 million euros year ago

Mar 23 2016

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00
Provider : Sadif Analytics Prime
$25.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.